Review Proposes 5-Pillar HIV Vaccine Access Plan for Africa as PrEP Still Cuts Risk by 90%
Updated
Updated · Devdiscourse · Jul 20
Review Proposes 5-Pillar HIV Vaccine Access Plan for Africa as PrEP Still Cuts Risk by 90%
2 articles · Updated · Devdiscourse · Jul 20
Summary
A review in Vaccines says HIV vaccine planning for Africa must start before any candidate reaches late-stage trials, warning that a successful shot without equitable access would repeat past global failures.
Three gaps drive that warning: weak regional manufacturing and supply security, limited trial and regulatory capacity, and delivery systems that still leave people blocked by stigma, clinic dependence and travel costs.
The paper’s five-pillar roadmap calls for diversified investment, binding equity commitments, logistical “war games,” integration with existing prevention services, and pre-funded post-licensure studies that could cost $40 million to $50 million.
That approach reflects current prevention limits: oral PrEP can cut HIV risk by more than 90% with consistent use, but adherence barriers and uneven access still blunt population-level impact across sub-Saharan Africa.
COVID-19 is the cautionary backdrop—high-income countries with about 16% of the world’s population secured an estimated 70% of 2021 vaccine doses—strengthening the case for African manufacturing, harmonized regulation and community-led rollout.
Should Africa save its current HIV programs or gamble on factories for a vaccine that doesn't exist?
Could the decline of Western health aid be the unexpected catalyst for Africa's pharmaceutical independence?
Africa’s HIV Prevention at a Crossroads: Lenacapavir Rollout, Five-Pillar Vaccine Roadmap, and the Fight Against Stigma and Funding Gaps (2024–2026)
Overview
This report highlights the December 2025 rollout of lenacapavir, a long-acting injectable that provides six months of HIV prevention with a single dose, following approvals by the U.S. FDA and European Commission. Public health leaders see lenacapavir as a breakthrough for underserved communities, but emphasize that its success depends on rapid, equitable distribution and strong community engagement. The rollout in Africa is part of a broader strategy, supported by global health organizations, to test delivery models and address challenges like stigma, funding cuts, and unequal access. These efforts are crucial for sustaining progress and moving closer to ending the HIV epidemic.